chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 4.0
Sex: U
Vaccine: IPV
Symptoms: No adverse event, Product storage error
Clinical narrative: patient received the IPV after the temperature excursion with no reported adverse event; Initial information was received on 29-Feb-2024 regarding an unsolicited valid  non-serious case received from a other health professional.  This case is linked to cases 2024SA070984, 2024SA071065 and 2024SA071311.  This case involves a 4 years, 5 months old and unknown gender patient who received the IPV (VERO) [IPOL] after the temperature excursion with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 26-Feb-2024, the patient received an unknown dose of suspect IPV (VERO) (Suspension for injection) (lot W1C831M, expiry date: 21-Nov-2025, strength: unknown) via intramuscular route in right arm for prophylactic vaccination (Immunization) and received the ipv after the temperature excursion with no reported adverse event (poor quality product administered) (Latency: same day).  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 11.0
Sex: M
Vaccine: MEN, TDAP
Symptoms: Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: more than 50% of the part red swollen and hot; more than 50% of the part red swollen and hot; more than 50% of the part red swollen and hot; Initial information receivedon 29-Feb-2024 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 11 years old male patient who experienced more than 50% of the part red swollen and hot after receiving diphtheria-2/tetanus/5 ac pertussis vaccine [adacel] and meningococcal a-c-y-w135 (t conj) vaccine [menquadfi].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Hpv Vaccine Vlp Rl1 4v (Yeast) (Gardasil) for Prophylactic vaccination.  On 26-Feb-2024, the patient received 0.5 ml of suspect Diphtheria-2/Tetanus/5 Ac Pertussis Vaccine Suspension for injection (lot U7870AA) (expiry date: 23-Aug-2025) (Strength: standard) (Frequency: once) via intramuscular route in the left upper arm for immunization.  On 26-Feb-2024, the patient received 0.5 ml of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine Solution for injection (lot U7938AA) (Expiry date: 28-Feb-2026) (Strength: standard) (Frequency: once) via intramuscular route in the left upper arm for immunization.  On an unknown date, the patient developed events of more than 50% of the part red swollen and hot (vaccination site erythema) (vaccination site warmth) (vaccination site swelling) (unknown latency).  It was reported, Medical Assistant called in because a patient had an adverse reaction. Patient was given MENQUADFI AND ADACEL on the same arm, on Monday (26Feb2024), and patient came into the office today (29Feb2024) and more than 50% of the part red swollen and hot. Caller also wanted to know what to do next.    Action taken: not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Unknown for the events
Age: 15.0
Sex: F
Vaccine: VARCEL
Symptoms: Circumstance or information capable of leading to medication error, Extra dose administered
Clinical narrative: Patient was placed on the schedule to receive Hep A vaccine that was still needed for school. I noticed patient's vaccine record wasn't reconciling correctly with Alert. I added the missing vaccine dates from system to Alert and fixed the reconciliation issue. I noticed on the vaccine record that an extra varicella was given, issue was escalated up to the CTS onsite.
Age: 73.0
Sex: F
Vaccine: RSV
Symptoms: Fatigue, Pyrexia
Clinical narrative: Fever and fatigue for 1-2 days
Age: 62.0
Sex: F
Vaccine: COVID19-2
Symptoms: Injection site vesicles, Peripheral swelling
Clinical narrative: swollen arm and blistering at injection site
Age: 1.0
Sex: F
Vaccine: MMRV
Symptoms: Pyrexia, Rash
Clinical narrative: high fever, rash
Age: 86.0
Sex: F
Vaccine: RSV
Symptoms: Injection site pain, Pain
Clinical narrative: Patient developed severe pain throughout the left side of her body from her neck down to the left side of her abdomen. The pain continued to be severe for 3 days before beginning to ease off, although the pain did not go away - she was still in a lot of pain for 1-2 weeks. The injection site is still a little sore despite being 4-5 weeks later.
Age: 29.0
Sex: F
Vaccine: VARZOS
Symptoms: Decreased appetite, Generalised oedema, Myalgia, Pain, Somnolence
Clinical narrative: groggy and sore on 2/15 muscle soreness. loss of appetite.. body started swelling in the next few days. when to the hospital 02/26.  "had a case of vasculitis" before she went in to hospital (saturday after the shot ~roughly a week after shot).      received steroids, breathing treatments and antibiotics. Discharched from the hospital on 3/2
Age: 29.0
Sex: F
Vaccine: VARZOS
Symptoms: Vasculitis
Clinical narrative: groggy and sore on 2/15 muscle soreness. loss of appetite.. body started swelling in the next few days. when to the hospital 02/26.  "had a case of vasculitis" before she went in to hospital (saturday after the shot ~roughly a week after shot).      received steroids, breathing treatments and antibiotics. Discharched from the hospital on 3/2
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: had Covid; had Covid; This is a spontaneous report received from a Consumer or other non HCP.  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Lot number: EL3249) and as dose 2, single (Lot number: EL9269) for covid-19 immunisation. The patient's relevant medical history included: "lactose intolerant" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "had Covid". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400057432 same patient/suspect vaccine; different dose/event;
Age: 94.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19-2, COVID19-2
Symptoms: COVID-19, Cough, Respiratory tract congestion, SARS-CoV-2 test positive
Clinical narrative: Congestion with cough. Mucinex 100mg/5ml every four hours as needed for cough
Age: 61.0
Sex: F
Vaccine: FLU4, UNK
Symptoms: Injected limb mobility decreased, Pain in extremity
Clinical narrative: Couldn't lift arm up or forward without assistance
Age: 61.0
Sex: F
Vaccine: FLU4, UNK
Symptoms: Mobility decreased, Ultrasound scan
Clinical narrative: Couldn't lift arm up or forward without assistance
Age: 56.0
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Cancer surgery, Chemotherapy, Computerised tomogram abdomen, Computerised tomogram pelvis, Hysterectomy
Clinical narrative: Diagnosed with Ovarian Cancer; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, intramuscular, batch number: 205A21A) dose was not reported, administered on 27-JUL-2021 for covid-19 prophylaxis. No concomitant medications were reported.  Patient stated that she received the vaccine on 27- JUL-2021 and 6 months later she was diagnosed with Ovarian cancer. Patient believed that the vaccine was the cause or triggered the diagnosis of ovarian cancer (dose number in series 1).  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of diagnosed with ovarian cancer was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0- Ovarian cancer. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Age: 56.0
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Ovarian cancer
Clinical narrative: Diagnosed with Ovarian Cancer; This spontaneous report received from a patient concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, intramuscular, batch number: 205A21A) dose was not reported, administered on 27-JUL-2021 for covid-19 prophylaxis. No concomitant medications were reported.  Patient stated that she received the vaccine on 27- JUL-2021 and 6 months later she was diagnosed with Ovarian cancer. Patient believed that the vaccine was the cause or triggered the diagnosis of ovarian cancer (dose number in series 1).  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of diagnosed with ovarian cancer was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0- Ovarian cancer. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Suspected vaccination failure; shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix.  Additional Information: GSK Receipt Date: 29-FEB-2024 This case was reported by a patient via interactive digital media. The reporter stated that, when someone he/she knew gets the shot they got shingles.  The reporter stated that he/she not getting it ever. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.
Age: 42.0
Sex: U
Vaccine: VARZOS
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: I had mine at 42; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of inappropriate age at vaccine administration in a 42-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included blister and pain.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate age at vaccine administration (Verbatim: I had mine at 42). The outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK Receipt Date: 27-FEB-2024 This case was reported by patient via interactive digital media. The patient stated that, first doctor gave him/her the vaccine even though he/she already had blistering and intense pain. After 7 weeks of horrible pain, the patient went back and thankfully had a doctor who gave him/her epilepsy medicines. Pain was gone within 24 hours. The patient received Shingrix, below than the recommended age limit, which led to inappropriate age at vaccine administration.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Inappropriate schedule of product administration
Clinical narrative: the second dose was administered a month early; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a 68-year-old female patient who received Herpes zoster (Shingrix) (batch number 2737J, expiry date 23-SEP-2025) for prophylaxis.   Concomitant products included Varicella zoster vaccine rgE (CHO) (Shingrix).   On 27-FEB-2024, the patient received the 2nd dose of Shingrix. On 27-FEB-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short (Verbatim: the second dose was administered a month early ). The outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK Receipt Date: 29-FEB-2024 The primary care manager reported that the 2nd dose was administered a month early which led to shortening of vaccination schedule. The reporter asked any information available. The reporter consented to follow up.
Sex: U
Vaccine: COVID19
Symptoms: Fall, Fracture, Joint dislocation
Clinical narrative: fractured; fall; I dislocated my shoulder; This is a spontaneous report received from a Consumer or other non HCP, Program ID:.   An 80-year-old patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in Nov2023 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE NUMBER UNKNWON. SINGLE), for COVID-19 immunisation. The following information was reported: FRACTURE (medically significant), outcome "unknown", described as "fractured"; FALL (medically significant), outcome "unknown"; JOINT DISLOCATION (medically significant), outcome "unknown", described as "I dislocated my shoulder". The event "fractured" required physician office visit.  Clinical course was reported as follows: patient stated that had to quit the job because of the fallings, that caused a shoulder dislocation, physicians discovered a fracture and the patient will have surgery. Patient can't drive or do anything with this risk for falls.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.
Age: 4.0
Sex: F
Vaccine: HIBV
Symptoms: No adverse event, Product preparation error
Clinical narrative: patient was administered ACTHIB diluent and not the lyophilized powder (with no reported adverse event); Initial information received on 29-Feb-2024 regarding an unsolicited valid non-serious case received from a physician.  This case involves a 4-year-old female patient was administered HIB (PRP/T) vaccine [ACT-HIB]. diluent and not the lyophilized powder (with no reported adverse event).  The patient's past medical history, medical treatment(s), vaccination(s), concomitant(s) and family history were not provided.  On 16-Feb-2024, the patient received 0.5 ml total dose of suspect HIB (PRP/T) vaccine, Powder and solvent for solution for injection (strength: unknown) (lot: UJ870AZ, expiry date: 24-Mar-2024) via intramuscular route in the left thigh for Immunization and patient was administered acthib diluent and not the lyophilized powder (with no reported adverse event) (product preparation error) (latency: same day).     This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.17
Sex: U
Vaccine: IPV
Symptoms: No adverse event, Poor quality product administered, Product storage error
Clinical narrative: received the IPV after the temperature excursion, with no reported adverse event; Initial information received from on 29-Feb-2024 regarding an unsolicited valid  non-serious case received from a other health professional.  This case is linked to cases 2024SA070984, 2024SA071451 and 2024SA071311.  This case involves a 2-month-old and unknown gender patient who received the IPV (VERO) [IPOL] after the temperature excursion, with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s), concomitant(s) and family history were not provided.   On 26-Feb-2024, the patient received an unknown dose of suspect IPV (VERO), Suspension for injection (strength: unknown) (lot: W1C831M, expiry date: 21-Nov-2025) via intramuscular route in the right thigh for Immunization and the patient received the ipv after the temperature excursion, with no reported adverse event (poor quality product administered) (latency: same day)    This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: Had shingles/ Suspected Vaccination failure; Had shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vaccination failure (Verbatim: Had shingles/ Suspected Vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Had shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingrix.   Additional Information: GSK Receipt Date: 26-FEB-2024 This case was reported by patient via interactive digital media. The patient had shingles. The reporter mentioned that not as bad as the side effects. The reporter stated that they spend 15 seconds telling him/her what it for and then another 90 seconds daring him/her to take it. The follow up would not possible as no contact details were available.
Sex: U
Vaccine: VARZOS, VARZOS
Symptoms: Herpes zoster, Pain, Vaccination failure
Clinical narrative: pain; Had the two shots then a year later got shingles/suspected Vaccination failure; Had the two shots then a year later got shingles in November last year; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix (unknown arm) and the 1st dose of Shingrix (unknown arm). In NOV-2023, 1 year after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Had the two shots then a year later got shingles/suspected Vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Had the two shots then a year later got shingles in November last year). On an unknown date, the patient experienced pain (Verbatim: pain). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported and the outcome of the pain was not resolved.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingrix and Shingrix.     It was unknown if the company considered the vaccination failure, shingles and pain to be related to Shingrix and Shingrix.   Additional Information: GSK Receipt Date: 26-FEB-2024 This case was reported by consumer via interactive digital media. Had the two shots than a year later got shingles in November last year and now have to live with a nerve blocker 3 months later still in pain. This case was considered as suspected vaccination failure as details regarding laboratory confirmation regarding shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
Sex: F
Vaccine: HEP
Symptoms: Expired product administered, No adverse event
Clinical narrative: No additional AE/PQC reported; FBE calling to report an AE on behalf of a Medical Assistant. Per FBE, a female patient was inadvertently administered an expired dose of RECOMBIVAX HB.  Caller stated the RECOMBIVAX HB expired on 02/15/2024, but was administered on 02/22/2024.  Cons; This spontaneous report was received from a medical assistant referring to a female patient of unknown age. Information about medical history, concurrent conditions and concomitant therapies was not provided.      On 22-FEB-2024, the patient was inadvertently vaccinated with an expired dose of hepatitis b vaccine (recombinant)(RECOMBIVAX HB) (second dose of the series, expiration date 15-FEB-2024; strength, dose, route, lot # were not reported) for prophylaxis (expired product administered). No additional adverse event was reported.   Lot # is being requested and will be submitted if received.
Sex: F
Vaccine: VARZOS
Symptoms: Discomfort, Herpes zoster, Pain, Quality of life decreased, Vaccination failure
Clinical narrative: Suspected vaccination failure; She has had a number of recurring painful bouts of shingles ever since; The pain and discomfort are interfering with her quality of life; The pain and discomfort are interfering with her quality of life; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a 54-year-old female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: She has had a number of recurring painful bouts of shingles ever since), pain (Verbatim: The pain and discomfort are interfering with her quality of life) and discomfort (Verbatim: The pain and discomfort are interfering with her quality of life). The outcome of the vaccination failure was unknown and the outcome of the shingles, pain and discomfort were not reported.   It was unknown if the reporter considered the vaccination failure, shingles, pain and discomfort to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure, shingles, pain and discomfort to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 28-Feb-2024 This case was reported by the patient's parent via interactive digital media. The patient received the shingles vaccines and they did not worked for her.  The reporter stated that the patient has had a number of recurring painful bouts of shingles ever since, and asked what could be done for someone like her daughter. Further stated that the pain and discomfort was interfering with the patients quality of life. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The follow-up could not be possible as no contact details were available.
Sex: M
Vaccine: VARZOS
Symptoms: Incomplete course of vaccination
Clinical narrative: patient did not receive 2nd dose yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 60-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (on 02-AUG-2021 received 1st dose).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: patient did not receive 2nd dose yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 26-FEB-2024 The RPH (registered pharmacist) reported that the patient received dose 1 of Shingrix and he was asking about getting dose 2 and if he needs to restart the series.  Till the time of reporting the patient did not receive the second dose of Shingrix, which led to an incomplete course of vaccination.
Sex: U
Vaccine: MMR
Symptoms: Intercepted product storage error
Clinical narrative: new MMR GSK Priorix had been in the freezer for a week/ storage error; This non-serious case was reported by a nurse via call center representative and described the occurrence of intercepted product storage error in a patient who received MMR (Priorix) for prophylaxis.   On an unknown date, the patient did not receive Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced intercepted product storage error (Verbatim: new MMR GSK Priorix had been in the freezer for a week/ storage error). The outcome of the intercepted product storage error was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 27-FEB-2024 The nurse called to inform that they had an issue where they received the new MMR GSK Priorix and did not realize it could not be put in the freezer. It had been in the freezer for a week and no doses had been administered, which led to an intercepted product storage error. According to the reporter, Priorix was confused with a Merck MMR vaccine that could be stored in the freezer.
Sex: U
Vaccine: TDAP
Symptoms: Expired product administered
Clinical narrative: an expired dose of Boostrix administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of expired vaccine used in a patient who received DTPa (Reduced antigen) (Boostrix) (batch number E3594, expiry date 18-JAN-2024) for prophylaxis.   On 26-FEB-2024, the patient received Boostrix. On 26-FEB-2024, an unknown time after receiving Boostrix, the patient experienced expired vaccine used (Verbatim: an expired dose of Boostrix administered). The outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 28-FEB-2024 The pharmacist was asking for Boostrix information beyond the expiration date, stated that a patient received an expired dose of Boostrix, which led to an expired vaccine used. The vaccine administration facility was the same as primary reporter.  The pharmacist declined to provide any patient information.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: N./A
Age: 78.0
Sex: M
Vaccine: UNK
Symptoms: Computerised tomogram thorax abnormal, Dyspnoea, Pulmonary thrombosis
Clinical narrative: Shortness of breath. Continued to the emergency room. Discovery of a blood clot in the lung and danger of terminal hearth-attack
Age: 86.0
Sex: F
Vaccine: RSV
Symptoms: Pain, Pain in extremity
Clinical narrative: Left arm Pain at time of vaccine continuing. Pain radiates into fingers
Age: 4.0
Sex: F
Vaccine: MMR
Symptoms: Oxygen saturation decreased, Pallor, Pruritus, Tongue pruritus, Urticaria
Clinical narrative: ITCHY TONGUE AND BODY WITH DEVELOP OF FEW HIVES, START TO GET PALE AND OXIGEN SATURATION DECREASING.
Age: 81.0
Sex: M
Vaccine: UNK
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse reactions occurred. Patient did not report any signs or symptoms of distress. The incorrect vaccine was given to the patient. Beyfortus was given when Abrysvo should have been given instead.
Age: 17.0
Sex: F
Vaccine: HIBV, TDAP
Symptoms: No adverse event, Wrong product administered
Clinical narrative: Incorrect vaccine was given to the patient. Patient received HIB vaccine instead of meningococcal conjugate vaccine.  Pt had no immediate reactions and left the office in stable condition.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Unevaluable event
Clinical narrative: N./A
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Unresponsive to stimuli, Wheezing
Clinical narrative: Admit date: 2/28/2024  Discharge date: 3/1/2024  Admitting Physician:    Discharge Physician:   Reason for Admission: acute encephalopathy   Discharge Problem List     * (Principal) Severe sepsis    Type 2 diabetes mellitus with hyperglycemia, without long-term current use of insulin   Lactic acidosis   COVID-19   High anion gap metabolic acidosis   Transaminitis   Acute kidney injury superimposed on chronic kidney disease   Chronic kidney disease, stage 3b   Acute respiratory failure   Bilateral pleural effusion   Hyperkalemia  Procedures: None  Consultations: Case Management, Intensivist, and Social Work, Hospice care   Hospital Course:91 YO female with past medical history significant for DM2 recently diagnosed, and smoking history (quit at 80yo), who presented to ED with complaints of altered mental status. At baseline she has advanced demential but daughter states she has been progressively worsening over the past week. Associated symptoms include progressive weakness leading to multiple falls but no loss of consciousness was reported. She also had increased urinary frequency but family denied noticing a productive cough, fever, chills, blood in the stool or urine. Her husband was sick one week earlier. On presentation she was hypoxic in the 80's and required bipap. Chest imaging was significant for bilateral pleural effusion and opacities bilaterally. LA >8 which improved to normal after IVF. All her labs were consistent with a multisystem shock-like state. Abdominal CT scan was unremarkable for abdominal acute pathology but lungs were noted to have a moderate right sided pleural effusion and a mild left sided pleural effusion with infiltrates suggestive, we suspect this is a parapneumonic effusion. She was somnolent but able to respond to her name but unable to follow commands. She had scattered rhonchi and wheezes in her lungs b/l throughout. She was admitted for severe sepsis secondary to pneumonia and was treated with broad spectrum antibiotics, fluid resuscitation, oxygen/bipap, and supportive measures. was consulted and ordered troponin. EKGs were reassuring for no presence of STEMI but given very high troponin cardiology was consulted. She was placed on heparin gtt and an ECHO revealed HFrEF and family did not want to persue further interventions such as a cardiac cath. Her husband is her POA. The entire family is focused on her comfort, and everyone voices that this is what she would want. Initially plans for a therapeutic/diagnostic paracentesis was discussed with family, however, overnight the patient continued to worsen. She developed afib with RVR and her kidney function continue to worsen making us suspect possibly a cardio-renal component. She is unable to clear her lactic acid, as her bicarb remain very low. We discussed goals of care with the family and they opted for comfort measures and wanted to speak with the hospice team. The hospice team met with the patient and orders were changed to reflect their/patient's wishes. She will be discharge. It was a pleasure caring for her.  Discharged to Hospice.
Age: 53.0
Sex: F
Vaccine: HEP
Symptoms: No adverse event, Wrong product administered
Clinical narrative: no adverse event. patient got Hepatitis B instead of TDaP ordered. she tolerated vaccine well. no new concerns
Age: 43.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, Chest discomfort, Computerised tomogram thorax normal, Cough, Dyspnoea
Clinical narrative: Admit date: 3/2/2024  Discharge date: 3/3/2024  Admitting Physician: MD   Attending Physician at the Time of Discharge: MD  Primary Care Physician: MD Reason for Admission: influenza, COVID>   Brief Summary of Hospital Stay: From the HPI of Dr.: "Very pleasant 44 F. Single, lives alone with her grandfather. Non smoker, very occasional social drinker only. Works at the Bus company.  1 day history of feeling unwell. Started out as having dry cough, sore throat, nausea, could not sleep. Symptoms progressed to SOB and mild chest discomfort when coughing. T taken was 100 degrees. Took Tylenol 1 g for her symptoms, yet they persisted.  Proceeded to have a check up at a nearby facility. Was observed with low oxygen levels while there. Was directed to the ED for further evaluation and MGT given hypoxia observed.  ED w/u show her dually positive for COVID-19 and Influenza A infections. She is not hypoxic at rest, but was tested 86-87% while ambulating. An elevated D dimer of >500 led to a CT chest exam. CT chest findings are negative for any acute PE or lung infiltrates."  Patient improved rapidly.  She was able to tolerate a diet.  She was able to ambulate on room air without desaturation. She felt stable to return home.  She will complete course of OSELTAMIVIR.   Issues Requiring Follow Up: none.  Discharged to Home
Age: 43.0
Sex: F
Vaccine: COVID19-2
Symptoms: Fibrin D dimer, Hypoxia, Influenza, Influenza A virus test positive, Insomnia
Clinical narrative: Admit date: 3/2/2024  Discharge date: 3/3/2024  Admitting Physician: MD   Attending Physician at the Time of Discharge: MD  Primary Care Physician: MD Reason for Admission: influenza, COVID>   Brief Summary of Hospital Stay: From the HPI of Dr.: "Very pleasant 44 F. Single, lives alone with her grandfather. Non smoker, very occasional social drinker only. Works at the Bus company.  1 day history of feeling unwell. Started out as having dry cough, sore throat, nausea, could not sleep. Symptoms progressed to SOB and mild chest discomfort when coughing. T taken was 100 degrees. Took Tylenol 1 g for her symptoms, yet they persisted.  Proceeded to have a check up at a nearby facility. Was observed with low oxygen levels while there. Was directed to the ED for further evaluation and MGT given hypoxia observed.  ED w/u show her dually positive for COVID-19 and Influenza A infections. She is not hypoxic at rest, but was tested 86-87% while ambulating. An elevated D dimer of >500 led to a CT chest exam. CT chest findings are negative for any acute PE or lung infiltrates."  Patient improved rapidly.  She was able to tolerate a diet.  She was able to ambulate on room air without desaturation. She felt stable to return home.  She will complete course of OSELTAMIVIR.   Issues Requiring Follow Up: none.  Discharged to Home
Age: 43.0
Sex: F
Vaccine: COVID19-2
Symptoms: Malaise, Nausea, Oropharyngeal pain, Oxygen saturation decreased, SARS-CoV-2 test positive
Clinical narrative: Admit date: 3/2/2024  Discharge date: 3/3/2024  Admitting Physician: MD   Attending Physician at the Time of Discharge: MD  Primary Care Physician: MD Reason for Admission: influenza, COVID>   Brief Summary of Hospital Stay: From the HPI of Dr.: "Very pleasant 44 F. Single, lives alone with her grandfather. Non smoker, very occasional social drinker only. Works at the Bus company.  1 day history of feeling unwell. Started out as having dry cough, sore throat, nausea, could not sleep. Symptoms progressed to SOB and mild chest discomfort when coughing. T taken was 100 degrees. Took Tylenol 1 g for her symptoms, yet they persisted.  Proceeded to have a check up at a nearby facility. Was observed with low oxygen levels while there. Was directed to the ED for further evaluation and MGT given hypoxia observed.  ED w/u show her dually positive for COVID-19 and Influenza A infections. She is not hypoxic at rest, but was tested 86-87% while ambulating. An elevated D dimer of >500 led to a CT chest exam. CT chest findings are negative for any acute PE or lung infiltrates."  Patient improved rapidly.  She was able to tolerate a diet.  She was able to ambulate on room air without desaturation. She felt stable to return home.  She will complete course of OSELTAMIVIR.   Issues Requiring Follow Up: none.  Discharged to Home
Age: 11.0
Sex: F
Vaccine: TDAP
Symptoms: Erythema, Pain in extremity, Peripheral swelling
Clinical narrative: Patient received immunization on 2/28/24.  On 3/2/24, patient's left arm was red, swollen, and painful.  Patient was seen in the emergency room and received an oral dose of Decadron and a prescription for Zyrtec and Keflex.  Patient followed up with PCP on 3/6/24 and symptoms have resolved.
Age: 62.0
Sex: M
Vaccine: COVID19-2
Symptoms: Abdominal pain, Abdominal tenderness, Abdominal wall haematoma, Cough, Ecchymosis
Clinical narrative: Admit date: 2/29/2024  Discharge date: 3/4/2024  Admitting Physician:   Attending Physician at the Time of Discharge:  Primary Care Physician:  Reason for Admission: Intramuscular HEmatoma  Brief Summary of Hospital Stay:  pmhx aflutter, COPD on 2L O2, T2DM, ESRD on dialysis, HTN, HLD, Laurence-Moon-Biedl Syndrome presented with complaint of abdominal pain, worsening cough, nausea. Found to have large right rectus intramuscular hematoma measuring up to 12.3 cm in length with active bleeding. Pt on warfarin for aflutter, reversed with vitamin K in the ED. Pt found to have hyperkalemia managed with lokelma in the ED. Pt transferred from ED to hospital. Surgery and IR consulted. No need for surgical intervention during this admission. Pt hemoglobin monitored throughout admission. Required 1 unit pRBCs 2/2 ABLA.  Pt continued to have hyperkalemia and developed EKG changes. Managed with calcium gluconate, insulin with dextrose, lokelma, and dialysis. For pt's ESRD - Nephrology consulted - managed with dialysis MWF, calcitriol, and Renvela. Pt's hemoglobin continued to stabilize, hyperkalemia resolved, and hematoma continued to reabsorb. Pt discharged home in stable condition.  Physical Exam:Constitutional - ill appearing, in NAD  HEENT - no JVD, no scleral icterus, EOM intact, wearing dark glasses Cardiovascular - RRR. No murmur appreciated. 1+ edema noted BL Pulmonary - CTA BL, breath sounds normal, no WOB,on 2L NC Abdominal -  Protuberant, tympanitic to percussion, non-tender in upper quadrants. Tenderness to palpation along lower quadrant ecchymosis. Ecchymosis over lower quadrants decreased in size. Right flank ecchymosis increased in size without tenderness to palpation. Extremities - no motor deficits, skin warm/dry Neurological - alert and oriented with no focal deficits    Issues Requiring Follow Up:  - Rectal Sheath Hematoma - STOP coumadin until reevalauted by PCP - Repeat CBC 3/11/2024 - Enhancing Lesion on Kidney - Consider dedicated CT/MRI - Follow up with PCP 3/12/2024 Discharged to Home
Age: 62.0
Sex: M
Vaccine: COVID19-2
Symptoms: Electrocardiogram change, Full blood count, Haemoglobin, Hyperkalaemia, Internal haemorrhage
Clinical narrative: Admit date: 2/29/2024  Discharge date: 3/4/2024  Admitting Physician:   Attending Physician at the Time of Discharge:  Primary Care Physician:  Reason for Admission: Intramuscular HEmatoma  Brief Summary of Hospital Stay:  pmhx aflutter, COPD on 2L O2, T2DM, ESRD on dialysis, HTN, HLD, Laurence-Moon-Biedl Syndrome presented with complaint of abdominal pain, worsening cough, nausea. Found to have large right rectus intramuscular hematoma measuring up to 12.3 cm in length with active bleeding. Pt on warfarin for aflutter, reversed with vitamin K in the ED. Pt found to have hyperkalemia managed with lokelma in the ED. Pt transferred from ED to hospital. Surgery and IR consulted. No need for surgical intervention during this admission. Pt hemoglobin monitored throughout admission. Required 1 unit pRBCs 2/2 ABLA.  Pt continued to have hyperkalemia and developed EKG changes. Managed with calcium gluconate, insulin with dextrose, lokelma, and dialysis. For pt's ESRD - Nephrology consulted - managed with dialysis MWF, calcitriol, and Renvela. Pt's hemoglobin continued to stabilize, hyperkalemia resolved, and hematoma continued to reabsorb. Pt discharged home in stable condition.  Physical Exam:Constitutional - ill appearing, in NAD  HEENT - no JVD, no scleral icterus, EOM intact, wearing dark glasses Cardiovascular - RRR. No murmur appreciated. 1+ edema noted BL Pulmonary - CTA BL, breath sounds normal, no WOB,on 2L NC Abdominal -  Protuberant, tympanitic to percussion, non-tender in upper quadrants. Tenderness to palpation along lower quadrant ecchymosis. Ecchymosis over lower quadrants decreased in size. Right flank ecchymosis increased in size without tenderness to palpation. Extremities - no motor deficits, skin warm/dry Neurological - alert and oriented with no focal deficits    Issues Requiring Follow Up:  - Rectal Sheath Hematoma - STOP coumadin until reevalauted by PCP - Repeat CBC 3/11/2024 - Enhancing Lesion on Kidney - Consider dedicated CT/MRI - Follow up with PCP 3/12/2024 Discharged to Home
Age: 62.0
Sex: M
Vaccine: COVID19-2
Symptoms: Nausea, Oedema, Red blood cell transfusion, Renal disorder
Clinical narrative: Admit date: 2/29/2024  Discharge date: 3/4/2024  Admitting Physician:   Attending Physician at the Time of Discharge:  Primary Care Physician:  Reason for Admission: Intramuscular HEmatoma  Brief Summary of Hospital Stay:  pmhx aflutter, COPD on 2L O2, T2DM, ESRD on dialysis, HTN, HLD, Laurence-Moon-Biedl Syndrome presented with complaint of abdominal pain, worsening cough, nausea. Found to have large right rectus intramuscular hematoma measuring up to 12.3 cm in length with active bleeding. Pt on warfarin for aflutter, reversed with vitamin K in the ED. Pt found to have hyperkalemia managed with lokelma in the ED. Pt transferred from ED to hospital. Surgery and IR consulted. No need for surgical intervention during this admission. Pt hemoglobin monitored throughout admission. Required 1 unit pRBCs 2/2 ABLA.  Pt continued to have hyperkalemia and developed EKG changes. Managed with calcium gluconate, insulin with dextrose, lokelma, and dialysis. For pt's ESRD - Nephrology consulted - managed with dialysis MWF, calcitriol, and Renvela. Pt's hemoglobin continued to stabilize, hyperkalemia resolved, and hematoma continued to reabsorb. Pt discharged home in stable condition.  Physical Exam:Constitutional - ill appearing, in NAD  HEENT - no JVD, no scleral icterus, EOM intact, wearing dark glasses Cardiovascular - RRR. No murmur appreciated. 1+ edema noted BL Pulmonary - CTA BL, breath sounds normal, no WOB,on 2L NC Abdominal -  Protuberant, tympanitic to percussion, non-tender in upper quadrants. Tenderness to palpation along lower quadrant ecchymosis. Ecchymosis over lower quadrants decreased in size. Right flank ecchymosis increased in size without tenderness to palpation. Extremities - no motor deficits, skin warm/dry Neurological - alert and oriented with no focal deficits    Issues Requiring Follow Up:  - Rectal Sheath Hematoma - STOP coumadin until reevalauted by PCP - Repeat CBC 3/11/2024 - Enhancing Lesion on Kidney - Consider dedicated CT/MRI - Follow up with PCP 3/12/2024 Discharged to Home
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Chest pain, Death, General physical health deterioration
Clinical narrative: Pt had four Covid MRNA Vaccines:  1-12-2021; 2-13-2021; 11-03-2021 and 4-7-2022.  He developed covid and had weakness.  Rolled out of bed and presented to ER 3-1-24 with chest pain and pneumothorax.  He declined and passed away on 3-2-24.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumothorax, SARS-CoV-2 test positive
Clinical narrative: Pt had four Covid MRNA Vaccines:  1-12-2021; 2-13-2021; 11-03-2021 and 4-7-2022.  He developed covid and had weakness.  Rolled out of bed and presented to ER 3-1-24 with chest pain and pneumothorax.  He declined and passed away on 3-2-24.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Aspiration, COVID-19, Death, Dysphagia
Clinical narrative: Admit date: 2/10/2024  Discharge date: 3/5/2024  Admitting Physician:    Discharge Physician: Reason for Admission: Acute hypoxic respiratory failure and sepsis 2/2 pneumonia  Hospital Course: Patient was an 82 year old female who presented to the emergency department with increased shortness breath after only being discharged a few days prior.  She was previously treated with a course of ceftriaxone and doxycycline.  In the emergency room, patient arrived tachycardic with hypoxia and was placed on BiPAP with improvement in her oxygenation.  She was started on vancomycin and Zosyn.  She was found to be COVID positive, and was started on remdesivir and Decadron.  Over the course of her stay, it became clear that patient was having significant dysphagia with aspiration events which was concerning for aspiration pneumonia.  She was continued on antibiotic therapy with Zosyn, however she continued to have significant aspiration events while she was here.  She was made NPO, and even with SLP evaluation she continued to aspirate.  Of note, she did not have any decision makers that were appropriate for her on file and she essentially had no family members that could make decisions for her.  Palliative Care was consulted and determined that she did not have decision-making capacity, but believed that G-tube would not reduce her risk of aspiration and that placing a G-tube for her given her mental state was medically futile.  An ethics committee consultation was made, and after reviewing her case, it was deemed that comfort care measures would be most appropriate for her, and her code status was changed to comfort care only.  Plan was to have her discharged back to her skilled nursing facility with hospice, however because her code status prior to arrival at hospice was full code, she would need a guardian to make the decision for her.  A court hearing was scheduled on 03/4 for appointment of guardianship.  Overnight on 03/04, patient was pronounced dead. She was comfortable during her final days.  Patient Expired.